Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BEAM-103

Monoclonal antibody · developed by Beam Therapeutics

Phase 1 Most advanced trial
BEAM Developer
1 Registered trials

What is BEAM-103?

BEAM-103 is a monoclonal antibody given as a single intravenous dose.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Developer
Beam Therapeutics Inc. (BEAM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07304791 Phase 1 Healthy Subjects Recruiting BEAM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Participant StudyHealthy Subjects

More from Beam Therapeutics

BEAM-201 Phase 1/2 BEAM-301 Phase 1/2 BEAM-302 Phase 1/2 Ristoglogene Autogetemcel Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BEAM page.

Follow BEAM, the company behind BEAM-103

See BEAM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BEAM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.